Aurora Cannabis launches its first medical CBD product in Uruguay



Bidiol is the only full-spectrum cannabis oil that is made entirely domestically

EDMONTON, AB, September 29, 2021 / PRNewswire / – Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company that defines the future of cannabinoids worldwide, has launched Bidiol, the first medicinal cannabis oil in Uruguay which is produced entirely domestically. The CBD oil is available in concentrations of 3% and 10% and is available in 10ml and 30ml bottles that are available from pharmacies across the country.

“The introduction of Bidiol took two years and is an essential part of our renewed strategy in Uruguay,” called Miguel Martin, Chief Executive Officer of Aurora Cannabis. “We have prioritized important international markets with the potential to sensibly expand their patient base. Our efforts include working with governments and local partners to do what works best in each market. There is no one-size-fits-all strategy – our approach has to be “smart and politically relevant.”

As a leader in the international cannabis market, Aurora has changed its strategy Uruguay focus solely on medical cannabis with the aim of making the country its continental production and distribution hub. Aurora’s operation in Uruguay includes one of the few GMP certified cannabis processing facilities in the country.

CBD oil is from the Ministry of Public Health by. authorized Uruguay to treat refractory epilepsy in children and adolescents.

Aurora develops its line of CBD oil in. Further Uruguay, with plans to expand its portfolio in the coming months.

About Aurora:

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquarters in Edmonton, Alberta, Aurora is a global cannabis pioneer committed to helping people improve their lives. The company’s portfolio of brands includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva, and KG7 CBD. Driven by science and innovation, and with a focus on high quality cannabis products, Aurora’s brands continue to assert themselves as industry leaders in the medical, performance, wellness and adult leisure markets wherever they hit the market. Learn more at and follow us on Twitter and LinkedIn.

Aurora common stock is traded on the TSX and NASDAQ under the symbol “ACB” and is part of the S & P / TSX Composite Index.

Forward-looking information

This press release contains statements that contain certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are often characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “can”, “will”. , “Potentially,” “proposed,” and other similar words or statements that certain events or conditions “may or will” occur. Forward-looking statements made in this press release include statements about new product introductions and product availability in pharmacies Uruguay. These forward-looking statements are only predictions. Various assumptions have been made in the conclusions or projections in the forward-looking statements in this press release. Forward-looking statements are based on management’s opinions, estimates and assumptions in light of management’s experience and perceptions about historical trends, current conditions and expected developments at the time the statements are made, such as current and future market conditions, the ability to maintain the SG&A costs correspond current expectations, the ability to achieve high margins in the Canadian consumer market, the current and future regulatory environment, and future permits and approvals. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes are relevant and appropriate in the given circumstances and that could cause actual events, results, activities, performance, prospects, opportunities or achievements to differ materially These may differ in the forward-looking statements projected, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the Reliva acquisition, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in the price of raw materials required, competition, effects and responses to the COVID-19 pandemic and other risks, uncertainties and factors that are covered under the heading “Risk Factors” in the annual information form lar of the company dated September 27, 2021 (the “AIF”) and filed with the Canadian Securities and Exchange Commission, available on the Company’s Issuer Profile on SEDAR at, and filed and available on the SEC website at The company advises that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and that other factors can also negatively affect the results. Readers are cautioned to weigh the risks, uncertainties and assumptions carefully in evaluating any forward-looking statements and not to place undue reliance on such information. The company is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information, future events or for other reasons, unless this is expressly required under applicable securities law.

SOURCE Aurora Cannabis Inc.

similar links